Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs*

References

• Cryer B. Nonsteroidal anti-inflammatory drugs and gastrointestinal disease. In: Feldman M, Scharschmidt BF, Sleisenger MH, editors. Sleisenger and Fordtran’s gastrointestinal and liver disease, 6th ed. Philadelphia: Saunders Co; 1998. p. 343–57
   Google Scholar
• Gabriel SE, Jaakkimainen L, Bombardier C. Risk for gastrointestinal complications related to use of nonsteroidal antiinflammatory drugs. A meta-analysis. Ann Int Med 1991;115:787–96
   Google Scholar
• Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. New Engl J Med 1999;340:1888–99
   PubMed Web of Science ®Google Scholar
• Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. New Engl J Med 2000;343:1520–8
   PubMed Web of Science ®Google Scholar
• Silverstein FE, Faich G, Goldstein JL, A, et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. J Am Med Assoc 2000;284:1247–55
   Google Scholar
• Watson DJ, Yu Q, Bolognese JA, Reicin AS, Simon TJ. The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysis. Curr Med Res Opin 2004;20(10):1539–48
   Google Scholar
• Gibberd FB. Dyspepsia in patients with rheumatoid arthritis. Acta Scand Rheum 1966;12:112–21
   PubMedGoogle Scholar
• Caruso I, Porro GB. Gastroscopic evaluation of anti-inflammatory agents. Br Med J 1980;280:75–8
   PubMed Web of Science ®Google Scholar
• Larkai EN, Smith JL, Lidsky MD, Graham DY. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 1987;82:1153–8
   PubMed Web of Science ®Google Scholar
• Armstrong CP, Blower AL. Nonsteroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut 1987;28:527–32
   PubMed Web of Science ®Google Scholar
• Buchanan WW, Brooks PM. Prediction of organ system toxicity with antirheumatic drug therapy. In: Bellamy N, editor. Prognosis in the rheumatic diseases. Dordrecht, the Netherlands: Kluwer Academic Publishers; 1991. p. 403–50
   Google Scholar
• Bloom BS. Cost of treating arthritis and NSAID-related gastrointestinal side-effects. Aliment Pharmacol Ther 1988;2(Suppl):131–9
   Google Scholar
• Bloom BS. Risk and cost of gastrointestinal side effects associated with nonsteroidal anti-inflammatory drugs. Arch Int Med 1989;149:1019–22
   PubMed Web of Science ®Google Scholar
• De Pouvourville G. The economic consequences of NSAID-induced gastropathy: the French context. Scand J Rheum 1992;96(Suppl):49–53
   Google Scholar
• Knill-Jones RJ. The economic consequences of NSAID-induced gastropathy in the United Kingdom and commentary on the article by G. de Pouvourville. Scand J Rheum 1992;96(Suppl.):59–62
   Google Scholar
• Johnson RE, Hornbrook MC, Hooker RS, Woodson GT, Schneidman R. Analysis of the costs of NSAID-associated gastropathy: experience in a US health maintenance organization. Pharmacoeconomics 1997;12:76–88
   Google Scholar
• Moore RA, Phillips CJ. Cost of NSAID adverse effects to the UK National Health Service. J Medical Economics 1999;2:45–55
   Google Scholar
• Rahme E, Joseph L, Kong SX, Watson DJ, LeLorier J. Gastrointestinal health care resource use and costs associated with nonsteroidal antiinflammatory drugs versus acetaminophen: retrospective cohort study of an elderly population. Arthritis Rheum 2000;43(4)917–24
   Google Scholar
• Watson DJ, Harper SE, Zhao P-L, Quan H, Bolognese JA, Simon TJ. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with non-selective COX-1/COX-2 inhibitors in osteoarthritis. Arch Int Med 2000;160: 2998–3003
   Google Scholar
• Watson DJ, Harper SE, Zhao P-L, Bolognese JA, Simon TJ. Gastrointestinal medications and procedures in osteoarthritis patients treated with rofecoxib compared with non-selective NSAIDs. Medscape Gen Med [serial on-line] 2001; 3(4). Available from Medscape General Medicine at www.medscape.com/viewarticle/408199. Accessed July 22, 2002
   Google Scholar
• Gottesdiener K, Schnitzer T, Fisher C, et al. Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis. Rheumatol 2002;41(9):1052–61
   PubMed Web of Science ®Google Scholar
• Curtis SP, Fisher C, Kafka S, et al. Treatment with etoricoxib (MK-0663), a COX-2 selective inhibitor, resulted in clinical improvement in knee osteoarthritis (OA) over 52 weeks. Ann Rheum Dis 2001;60\(Suppl. 1):229–30
   Google Scholar
• Fisher CA, Curtis SP, Resnick H, et al. Treatment with etoricoxib, a COX-2 selective inhibitor, resulted in clinical improvement in knee and hip osteoarthritis (OA) over 52 weeks. Arthritis Rheum 2001;44 (Suppl. 9):S135
   Google Scholar
• Leung AT, Malmstrom K, Gallacher AE, et al. Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: a randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial. Curr Med Res Opin 2002;18:49–58
   PubMed Web of Science ®Google Scholar
• Curtis SP, Losada B, Bosi-Ferraz M, et al. Etoricoxib and diclofenac demonstrate similar efficacy in a 174-week randomized study of rheumatoid arthritis patients. Arthritis Rheum 2003;48 (Suppl.9):S124–S125
   Google Scholar
• Collantes E, Curtis SP, Lee KW, et al. A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. BMC Family Practice [serial on-line] 2002;3:10. Available from BioMedCentral at http://www.biomedcentral.com/1471–2296/3/10/ Accessed March 15, 2004
   Google Scholar
• Matsumoto AK, Melian A, Mandel DR, McIlwain HH, Borenstein D, Zhao PL, Lines CR, Gertz BJ, Curtis S and the Etoricoxib Rheumatoid Arthritis Study Group. A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. J Rheumatol 2002;29:1623–30
   Google Scholar
• Matsumoto AK, Collantes E, Melian A, et al. Treatment with etoricoxib resulted in clinical improvement of rheumatoid arthritis (RA) in two randomized active comparator-controlled 52-week trials. Ann Rheum Dis 2003;62\(Suppl. 1):185
   Google Scholar
• Pallay RM, Seger W, Adler JL, et al. Etoricoxib reduced pain and disability and improved quality of life in patients with chronic low back pain: a 3 month, randomized, controlled trial. Scand J Rheumatol 2004;33:1–12)
   PubMed Web of Science ®Google Scholar
• Birbara CA, Puopolo AD, Munoz DR, et al. Treatment of chronic low back pain with etoricoxib, a new cyclo-oxygenase-2 selective inhibitor: improvement in pain and disability – a randomized, placebo-controlled, 3-month trial. J Pain 2003;4:307–15
   PubMed Web of Science ®Google Scholar
• Melian A, van der Heijde DM, James MK, et al. Etoricoxib in the treatment of ankylosing spondylitis (AS). Arthritis Rheum 2002;46\(Suppl.9):S432
   Google Scholar
• Hunt RH, Harper S, Callegari P, et al. Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib. Aliment Pharmacol Ther 2003;17:201–10
   PubMed Web of Science ®Google Scholar
• Hunt RH, Harper S, Watson DJ, et al. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am J Gastroenterol 2003;98:1725–33
   PubMed Web of Science ®Google Scholar
• Barner A. Review of clinical trials and benefit/risk ratio of meloxicam. Scand J Rheumatol 1996;25(Suppl 102):29–37
   Web of Science ®Google Scholar
• CATAFLAM/VOLTAREN/VOLTAREN X-R [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2003
   Google Scholar
• EC-NAPROSYN/NAPROSYN/ANAPROX/ANAPROX DS [package insert]: Nutley, NJ: Hoffman-La Roche Inc; 2003
   Google Scholar
• Pocock SJ, Clayton TC, Altman DG. Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. Lancet 2002;359:1686–9
   Google Scholar
• Pellissier JM, Straus WL, Watson DJ, Kong SX, Harper SE. Economic evaluation of rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs for the treatment of osteoarthritis. Clin Ther 2001;23(7):1061–79
   Google Scholar
• Moore A, Phillips C, Hunsche E, Pellissier JM, Kingslake S, Kong SX. Cost-effectiveness of etoricoxib compared to traditional NSAIDs in the UK. Ann Rheum Dis 2003;62(Suppl 1):354
   Google Scholar